In recent trials of MDM2 inhibitors, intermittent treatment schedules have helped mitigate dose-limiting hematologic toxicities while maintaining efficacy.51 In a phase I trial (NCT01877382), the MDM2 antagonist milademetan (DS-3032), which inhibits the MDM2-p53 interaction at nanomolar concentrations in vitro, demonstrated antitumor activity in patients with advanced liposarcoma, solid tumors, or lymphomas when administered with an intermittent dosing schedule (260 mg once daily on days 1-3 and days 15-17 every 28 days). The gene discussed is MDM2; the disease is lymphoma.